Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer

被引：0

作者：

Laura Mezquita

Marianne Oulhen

Agathe Aberlenc

Marc Deloger

Mihaela Aldea

Aurélie Honore

Yann Lecluse

Karen Howarth

Luc Friboulet

Benjamin Besse

David Planchard

Françoise Farace

机构：

[1] Gustave Roussy,

[2] Université Paris-Saclay,undefined

[3] Department of Medicine,undefined

[4] Medical Oncology Department,undefined

[5] Hospital Clinic of Barcelona,undefined

[6] Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors,undefined

[7] IDIBAPS,undefined

[8] Gustave Roussy,undefined

[9] Université Paris-Saclay,undefined

[10] “Rare Circulating Cells” Translational Platform,undefined

[11] CNRS UMS3655—INSERM US23 AMMICA,undefined

[12] INSERM,undefined

[13] U981 “Identification of Molecular Predictors and new Targets for Cancer Treatment”,undefined

[14] Gustave Roussy,undefined

[15] Université Paris-Saclay,undefined

[16] Bioinformatics Platform,undefined

[17] CNRS UMS3655—INSERM US23 AMMICA,undefined

[18] Gustave Roussy,undefined

[19] Université Paris-Saclay,undefined

[20] Genomic Platform,undefined

[21] CNRS UMS3655—INSERM US23 AMMICA,undefined

[22] Gustave Roussy,undefined

[23] Université Paris-Saclay,undefined

[24] “Flow cytometry and Imaging” Platform,undefined

[25] CNRS UMS3655—INSERM US23AMMICA,undefined

[26] Inivata Ltd,undefined

[27] Babraham Research Park,undefined

来源：

British Journal of Cancer | 2024年 / 130卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：682 / 693

页数：11

共 50 条

[21] How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)
Tabbo, Fabrizio
Pisano, Chiara
Mazieres, Julien
Mezquita, Laura
Nadal, Ernest
Planchard, David
Pradines, Anne
Santamaria, David
Swalduz, Aurelie
Ambrogio, Chiara
Novello, Silvia
Ortiz-Cuaran, Sandra
CANCER TREATMENT REVIEWS, 2022, 103
[22] Molecular mechanism and clinical outcome of non-small-cell lung cancer patients with high BRAF expression
Uehara, Yuji
TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 401 - 404
[23] Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer
Kim, Young Hak
JOURNAL OF THORACIC DISEASE, 2016, 8 (09) : 2369 - 2371
[24] BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.
Dagogo-Jack, Ibiayi
Martinez, Pablo
Yeap, Beow Y.
Ambrogio, Chiara
Lydon, Christine A.
Nguyen, Tom
Iafrate, A. John
Lennerz, Jochen K.
Johnson, Bruce E.
Shaw, Alice Tsang
Awad, Mark M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] Clinical Utility of Circulating Tumour Cell Detection in Non-Small-Cell Lung Cancer
Alberto Fusi
Robert Metcalf
Matthew Krebs
Caroline Dive
Fiona Blackhall
Current Treatment Options in Oncology, 2013, 14 : 610 - 622
[26] Clinical Utility of Circulating Tumour Cell Detection in Non-Small-Cell Lung Cancer
Fusi, Alberto
Metcalf, Robert
Krebs, Matthew
Dive, Caroline
Blackhall, Fiona
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (04) : 610 - 622
[27] Non-small-cell lung cancer: how to manage BRAF-mutated disease
Guaitoli, Giorgia
Zullo, Lodovica
Tiseo, Marcello
Dankner, Matthew
Rose, April A. N.
Facchinetti, Francesco
DRUGS IN CONTEXT, 2023, 12
[28] Circulating biomarkers and tumour molecular profiling in patients with non-small cell lung cancer
Karampini, Elena
Farah, Hassan
Kamal, Nahid
Cane, Paul
Moorhead, Jane
Pomplun, Sabine
King, Juliet
Sethi, Tariq
Spicer, James
McCaughan, Frank
EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[29] KRAS and BRAF Double Mutations and Functional Classes of BRAF Mutations in Non-small-cell Lung Cancers
Bourhis, Amelie
Remoue, Annabelle
Uguen, Arnaud
CLINICAL LUNG CANCER, 2020, 21 (04) : E240 - E242
[30] BRAF mutations in non-small cell lung cancer
Luk, Peter P.
Yu, Bing
Ng, Chiu Chin
Mercorella, Belinda
Selinger, Christina
Lum, Trina
Kao, Steven
O'Toole, Sandra A.
Cooper, Wendy A.
TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (02) : 142 - 148

← 1 2 3 4 5 →